US Bancorp’s Melinta Therapeutics, Inc. Common Stock MLNT Stock Holding History

US Bancorp’s Portfolio MLNT Stock Details MLNT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-44	Closed	-$2K	–	3748
2018 Q1	$2K	Buy	+44	New	+$2.89K	﹤0.01%	3518

Other funds holding MLNT

Oikos Holdings New York $422M AUM 13.79% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

US Bancorp's MLNT Position: Q2 2018 in Review

US Bancorp sold out of Melinta Therapeutics, Inc. Common Stock (MLNT) in Q2 2018, closing a stake of 44 shares — an estimated $2K sold.

US Bancorp first reported a position in MLNT in Q1 2018 and held it in 1 quarter. The position peaked at $2K in Q1 2018. 87 funds tracked by Wall St. Rank hold MLNT as of Q2 2018.

US Bancorp reported no remaining Melinta Therapeutics, Inc. Common Stock position as of Q2 2018 after selling out during the quarter.
US Bancorp sold 44 Melinta Therapeutics, Inc. Common Stock shares in Q2 2018, an estimated $2K.
US Bancorp first reported a position in Melinta Therapeutics, Inc. Common Stock in Q1 2018 and held it in 1 quarter.
US Bancorp's Melinta Therapeutics, Inc. Common Stock position peaked at $2K in Q1 2018.
87 funds tracked by Wall St. Rank held Melinta Therapeutics, Inc. Common Stock as of Q2 2018.

Based on US Bancorp's 13F filing for Q2 2018, filed 8 Aug 2018.